Triple-negative breast cancer (TNBC) is characterized by the absence of three key receptors in cancer cells—estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)—making TNBC more difficult to treat. This evidence concerns the gene ERBB2 and cancer.